Rigel Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Rigel Pharmaceuticals
RIGL Stock  USD 46.83  3.55  8.20%   
Rigel Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Rigel Pharmaceuticals' valuation are provided below:
Gross Profit
234.4 M
Profit Margin
0.4017
Market Capitalization
785.6 M
Enterprise Value Revenue
2.5121
Revenue
282.1 M
There are over one hundred nineteen available trending fundamental ratios for Rigel Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to check out Rigel Pharmaceuticals' recent fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 837.8 M this year. Enterprise Value is expected to rise to about 811.9 M this year

Rigel Pharmaceuticals Total Revenue

216.48 Million

Check Rigel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rigel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 9.6 M or Total Revenue of 216.5 M, as well as many indicators such as Price To Sales Ratio of 1.8, Dividend Yield of 0.0 or PTB Ratio of 109. Rigel financial statements analysis is a perfect complement when working with Rigel Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Rigel Stock
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.

Rigel Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets144.3 M188.6 M153.3 M
Pretty Stable
Short and Long Term Debt Total72.4 M69 M29.5 M
Slightly volatile
Other Current Liabilities14.7 M28.3 M18.8 M
Slightly volatile
Total Current Liabilities76.4 M72.8 M38.4 M
Slightly volatile
Property Plant And Equipment Net369.3 K388.7 K5.7 M
Very volatile
Accounts Payable4.3 M3.8 M4.7 M
Slightly volatile
Cash33.9 M65.3 M32.6 M
Slightly volatile
Non Current Assets Total34.9 M33.2 M14 M
Slightly volatile
Non Currrent Assets Other1.2 M1.3 M1.2 M
Pretty Stable
Cash And Short Term Investments120.7 M88.9 M119.7 M
Slightly volatile
Net Receivables50.3 M47.9 M17.1 M
Slightly volatile
Common Stock Total Equity210.1 K200.1 K134.3 K
Slightly volatile
Common Stock Shares Outstanding19.1 M20.3 M14.5 M
Slightly volatile
Liabilities And Stockholders Equity144.3 M188.6 M153.3 M
Pretty Stable
Non Current Liabilities Total117.6 M112 M41.2 M
Slightly volatile
Other Current Assets12.3 M11.7 M6.8 M
Slightly volatile
Other Stockholder Equity893.5 M1.6 B1.1 B
Slightly volatile
Total Liabilities194 M184.8 M79.6 M
Slightly volatile
Property Plant And Equipment Gross654.4 K688.9 K7.3 M
Very volatile
Total Current Assets134.2 M155.4 M140.8 M
Pretty Stable
Short Term Debt9.1 M8.7 M5.7 M
Slightly volatile
Common Stock19.7 K20.7 K94.1 K
Very volatile
Other Liabilities63.7 M60.6 M23.2 M
Slightly volatile
Other Assets547.2 K576 K915.1 K
Slightly volatile
Short Term Investments22.5 M23.7 M83.5 M
Slightly volatile
Property Plant Equipment732.7 K771.3 K3.1 M
Slightly volatile
Capital Surpluse1.3 B1.6 B1.2 B
Slightly volatile
Deferred Long Term Liabilities77 K81 K3.2 M
Slightly volatile
Non Current Liabilities Other54.3 M51.7 M17.8 M
Slightly volatile
Net Invested Capital49.8 M56.7 M77 M
Slightly volatile
Net Working Capital57.7 M64.6 M81.9 M
Slightly volatile
Capital Stock15.4 K16.2 K141.8 K
Slightly volatile
Long Term Debt Total24.5 M45.4 M19.2 M
Slightly volatile
Capital Lease Obligations243.7 K256.5 K17.6 M
Slightly volatile
Short and Long Term Debt8 M8.4 M7.3 M
Slightly volatile

Rigel Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.7 M2 M1.5 M
Slightly volatile
Total Revenue216.5 M206.2 M75.6 M
Slightly volatile
Other Operating Expenses105.3 M178.3 M115.1 M
Slightly volatile
Research Development25.5 M26.9 M51 M
Slightly volatile
Total Operating Expenses104.5 M156.9 M112.4 M
Slightly volatile
Selling General Administrative136.5 M130 M64.4 M
Slightly volatile
Non Operating Income Net Other936.5 K786.6 K807.5 K
Pretty Stable
Non Recurring1.1 M1.2 M2.8 M
Slightly volatile
Interest Income1.3 M2.4 M971.7 K
Slightly volatile
Reconciled Depreciation2.7 M2.6 M974.9 K
Slightly volatile

Rigel Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow31.9 M37.7 M28.3 M
Slightly volatile
Depreciation1.7 M2 M1.5 M
Slightly volatile
Capital Expenditures338.6 K356.4 K2.2 M
Very volatile
End Period Cash Flow33.9 M65.3 M32.6 M
Slightly volatile
Stock Based Compensation8.9 M14.3 M9.3 M
Slightly volatile
Change To Netincome7.6 M11.8 M10.1 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.81.9104
Slightly volatile
Days Sales Outstanding64.1576.25114
Slightly volatile
Stock Based Compensation To Revenue0.07550.07950.8087
Slightly volatile
Capex To Depreciation0.01380.01451.6146
Very volatile
EV To Sales1.821.92102
Slightly volatile
Inventory Turnover2.942.80.8585
Slightly volatile
Days Of Inventory On Hand128135955
Slightly volatile
Sales General And Administrative To Revenue1.341.422.6877
Slightly volatile
Research And Ddevelopement To Revenue0.140.155.2901
Slightly volatile
Capex To Revenue2.0E-42.0E-40.1934
Slightly volatile
Cash Per Share4.815.0617.8391
Slightly volatile
Intangibles To Total Assets0.10.150.1165
Slightly volatile
Current Ratio2.332.456.7791
Slightly volatile
Receivables Turnover3.683.8813.2393
Pretty Stable
Graham Number2.242.352.8994
Slightly volatile
Capex Per Share0.00220.002412.082
Slightly volatile
Revenue Per Share15.1311.7319.9013
Slightly volatile
Interest Debt Per Share4.224.4414.7113
Slightly volatile
Debt To Assets0.350.330.2166
Slightly volatile
Operating Cycle354182676
Pretty Stable
Ebt Per Ebit0.820.681.022
Very volatile
Long Term Debt To Capitalization0.540.850.535
Slightly volatile
Total Debt To Capitalization0.90.850.5431
Slightly volatile
Quick Ratio2.232.356.7357
Slightly volatile
Net Income Per E B T1.11.091.004
Slightly volatile
Cash Ratio1.831.031.245
Slightly volatile
Days Of Inventory Outstanding128135955
Slightly volatile
Days Of Sales Outstanding64.1576.25114
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.940.91.2036
Very volatile
Fixed Asset Turnover501477104
Slightly volatile
Debt Ratio0.350.330.2166
Slightly volatile
Price Sales Ratio1.81.9104
Slightly volatile
Asset Turnover1.030.980.5144
Slightly volatile

Rigel Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap837.8 M441.1 M560.1 M
Pretty Stable
Enterprise Value811.9 M406.9 M526.5 M
Pretty Stable

Rigel Fundamental Market Drivers

Forward Price Earnings8.3333
Cash And Short Term Investments77.3 M

Rigel Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rigel Pharmaceuticals Financial Statements

Rigel Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Rigel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue32 M33.6 M
Total Revenue206.2 M216.5 M
Cost Of Revenue16.8 M30 M
Stock Based Compensation To Revenue 0.08  0.08 
Sales General And Administrative To Revenue 1.42  1.34 
Research And Ddevelopement To Revenue 0.15  0.14 
Revenue Per Share 11.73  15.13 
Ebit Per Revenue 0.12  0.13 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
How To Invest In Rigel
Details
Is Rigel Stock a good investment?
Details
What is Rigel Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.086
Earnings Share
6.19
Revenue Per Share
15.806
Quarterly Revenue Growth
0.256
Return On Assets
0.3893
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY